detected in 48.3% of patients with active epilepsy. NCC is a chronic progressive disease, and the severity of the symptoms has been related to the number of cysts, their location, the stage of infection, and the intensity of host inflammatory immune response in the brain. Recently, we have reported an alarmingly high incidence of asymptomatic NCC cases (29.0%) among family members of symptomatic NCC patients [4] . Similarly, asymptomatic NCC cases were also found among otherwise healthy control subjects in another study from Latin America [5] .
The heterogeneity in the clinical presentation of the disease depends on the factors related to the parasite and the hosts, but even this requires more evidence. Toll-like receptors (TLRs) can act as central host factors involved in modulating the induction of several host genes through a complex network of signaling [6, 7] . TLRs are expressed on cells of the innate immune system and recognize distinct pathogen-associated molecular patterns (PAMPs). Thirteen mammalian TLR paralogues have now been identified [8] . There are various studies that show that particular TLRs are up-regulated in nerve tissue during infection, trauma, or autoimmune diseases [9] [10] [11] . The exact functional significance of TLRs in the context of CNS infection remains largely unknown. A recent study reported increased expression of TLRs during murine cysticercosis and suggested that TLRs might play a complex role in the CNS immune response to parasitic infection [12] . A study on the mouse model of Trypanosoma gondii infection showed a neuroprotective role of TLR2 [13] ; another study did not find any role of TLR2, TLR4, TLR6, or TLR9 in controlling T. gondii replication in the CNS [14] . The discrepancy regarding the functional importance of TLRs in the host response may be attributable to genetic variations in TLRs responsible for modulating the immune response. Helminth glycans can promote maturation of dendritic cells using TLR4 signaling, which drives Th2 (anti-inflammatory) immune responses [15] . In vivo and in vitro evidence indicates the polarization of immune response after helminth infection [16] [17] [18] . Studies on murine Taenia crassiceps infection have reported that proinflammatory cytokine production was also influenced by the signaling of certain neuropeptides that contributed to granuloma development [19, 20] . Increased expression of Th2 cytokines in asymptomatic NCC, in contrast with a predominance of Th1 cytokines in symptomatic NCC, has been reported [21] . Because TLR4 signaling is also responsible for inducing anti-inflammatory cytokines by interacting with helminth glycans [15] , there is a possibility that variation in the TLR4 gene results in altered TLR4 signaling and induction of proinflammatory cytokines, which results in symptomatic NCC. Medzhitov et al [22] showed that a mutant of TLR4 can induce the expression of inflammatory cytokines. A recent study showed that there was increased expression of proinflammatory cytokines in individuals heterozygous for TLR4 Asp299Gly [23] . This study raised a possibility that TLR4 polymorphism may result in a Th1 type of immune response. The 2 most common types of genetic variations in TLR4 are the nonsynonymous single-nucleotide polymorphism (SNP) Asp/Gly at amino acid 299 due to A/G transition and Thr/Ile at amino acid 399 due to C/T transition. In this study, we investigated the role of TLR4 Asp299Gly and Thr399Ile polymorphisms and their role in the development of symptomatic NCC.
MATERIALS AND METHODS

Study subjects.
A total of 140 NCC subjects (82 symptomatic subjects with active epilepsy and 58 asymptomatic subjects) and 150 healthy control subjects were included in the study. Diagnosis of NCC-related active epilepsy in patients was based on clinical, immunological, neuroimaging (ie, magnetic resonance imaging), and epidemiological criteria [24] . Active epilepsy was defined in a patient who had у2 episodes of seizures, 1 of which had occurred within the previous 5 years, regardless of antiepileptic drug treatment as prescribed by the International League against Epilepsy. Asymptomatic case patients were defined as individuals with no evidence or history of seizure, sensory or motor neurofocal deficit, cranial nerve involvement, and psychiatric or behavioral abnormalities. The Institute's ethics committee approved the work, and all individuals who were included in the study consented to enrollment.
Genomic DNA extraction. Peripheral blood was collected in EDTA vials from the study subjects, and genomic DNA was extracted from total blood using salting-out method and purified using the phenol-chloroform method [25] . DNA samples were stored at Ϫ20ЊC until used.
TLR4 (Asp299Gly and Thr399Ile) genotyping. We determined TLR4 genotypes by polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) based method, as previously described for both Asp299Gly and Thr399Ile SNP [26] . The primer sequences for TLR4 Asp299Gly were: forward 5 -GATTAGCATACTTAGACTACTACCTCC-ATG-3 and reverse 5 -GATCAACTTCTGAAAAAGCATTCC-CAC-3 , and primer sequences for TLR4 Thr399Ile were: forward 5 -GGTTGCTGTTCTCAAAGTGATTTTGGGAGAA-3 and reverse 5 -ACCTGAAGACTGGAGAGTGAGTTAAAT-GCT-3 (Sigma, USA). All PCR amplifications were performed in a 20-mL volume containing 10X assay buffer, 200 mM each of dATP, dCTP, dGTP, dTTP, 0.1 mM of each primer, 1.0 U of Taq DNA polymerase (Bangalore Genei). PCR conditions were as follows: an initial denaturation at 94ЊC for 5 min, followed by 35 cycles of denaturing at 94ЊC for 30 s, annealing at 55ЊC for 30 s, and extension at 72ЊC for 30 s, and a final extension at 72ЊC for 5 min and cooling to 4ЊC. Template-free water was used as a negative control. After amplification, the purified 4-mL PCR products were subjected to restriction digestion by NcoI restriction endonuclease (Fermentas) for TLR4 Asp299Gly and by HinfI for TLR4 Thr399Ile with 1 mL 10X enzyme buffer (Fermentas) overnight at 37ЊC. The digested DNA fragments were then separated on 3% agarose gel electrophoresis. After digestion, fragment sizes for carriers of the polymorphic allele decreased from 249 base-pairs (wild-type) to 223 base-pairs for the 299 residue, and from 406 base-pairs (wild-type) to 377 base-pairs for the 399 residue. All of the experiments were repeated twice for the confirmation of RFLP results.
Statistical analysis. The SPSS 15.0 statistical package (SPSS) was used for data management and analysis. The x 2 test was used for comparison between the NCC case patients and control subjects. Independent Student's t test was performed to compare continuous data (eg, age). To estimate the association of TLR4 (Asp299Gly and Thr399Ile) polymorphisms with NCC susceptibility (after adjusting for age and sex), logistic regression analysis was applied. Adopted recessive model was used to estimate the association of variant genotype with Table 1 ). Of 140 NCC subjects, 82 were symptomatic and 58 were asymptomatic. All the symptomatic patients had a history of seizures (ie, active epilepsy). In the symptomatic NCC group, calcified cysts, multiple-stage cysts, degenerating cysts, healed cysts, and vesicular stage cysts were present in 27 (32.92%), 23 (28.05%), 17 (20.73%), 10 (12.19%), and 5 (6.09%) of the patients, respectively, whereas in the asymptomatic group, calcified cysts, healed cysts, multiple-stage cysts, degenerating cysts, and vesicular stage cysts were present in 24 (41.37%), 15 (25.86%), 12 (20.68%), 4 (6.89%) and 3 (5.17%) of the patients, respectively. In both groups of individuals with NCC cases, cysts were located in the parenchymal region of the brain. On comparing the different stages between the symptomatic and asymptomatic NCC groups, only the presence of degenerating stage cysts was found to be significantly associ-ated with symptomatic NCC (20.73% vs 6.89%; ) P p .040 ( Table 2) .
RESULTS
Characteristics of NCC patients and control
TLR4 (Asp299Gly and Thr399Ile) polymorphisms in NCC patients and control subjects. The genotypic distribution of both TLR4 Asp299Gly and Thr399Ile polymorphism demonstrated an increased risk of NCC in patients with Asp/Gly genotype ( ; odds ratio [OR], 4.57; 95% confidence in-P ! .001 terval [CI], 2.60-8.04) and Thr/Ile genotype ( ; OR, P p .003 3.39; 95% CI, 1.52-7.56), respectively. Because the frequency of variant genotypes of both of the polymorphisms was quite low, we adopted a recessive model, and the association of NCC was calculated. The Gly (Asp/Gly plus Gly/Gly) and Ile (Thr/ Ile plus Ile/Ile) carriers were significantly associated with NCC ( ; OR, 4.52; 95% CI, 2.59-7.87) and ( ; OR, P ! .001 P p .003 3.18; 95% CI, 1.47-6.87), respectively, compared with the control group. The presence of Gly and Ile increased the risk for the development of NCC. Patients with NCC showed a significantly higher prevalence of the Gly (23.2% vs 8.0%; P ! ; OR, 3.48; 95% CI, 2.11-5.74) and Ile alleles (9.6% vs .001 3.7%;
; OR, 2.80; 95% CI, 1.36-5.77) ( Table 3 ). P p .005 Furthermore, to analyze the additive effect of both of the polymorphisms, haplotype analysis was performed. The frequency of haplotypes containing Gly/Thr was 0.04 in the control group and 0.21 in the NCC group. We found a positive association of haplotypes containing Gly/Thr with NCC (P ! ; OR, 6.25; 95% CI, 3.33-11.72). In contrast to the control .001 population, a new haplotype (Asp/Ile) was found in the patient group; however, there was no significant difference in the fre- quency of this haplotype in the patient group, compared with its frequency in the control group (Figure 1 ).
Association of TLR polymorphisms with symptomatic and asymptomatic NCC cases. TLR Asp299Gly (
; OR, P ! .001 9.16; 95% CI, 4.81-17.44) and TLR4 Thr399Ile ( ; OR, P ! .001 5.89; 95% CI, 2.54-13.65) genotypes were significantly associated with symptomatic NCC, when the NCC group was compared with the control group. Because the frequency of variant genotypes of both the polymorphisms was quite low, we adopted recessive model, and the association of NCC was calculated. The Gly (Asp/Gly plus Gly/Gly) ( (Table 4 ).
DISCUSSION
In this case-control study, TLR4 (Asp299Gly and Thr399Ile) gene polymorphisms were analyzed in patients with NCC and control subjects without NCC. We found a significant association between Asp299Gly and Thr399Ile genotypes of the TLR4 gene and susceptibility to NCC. Furthermore, both gene polymorphisms were also significantly associated with the development of symptomatic NCC. Testing for allele frequency dif- ferences between patients and control subjects revealed that variant alleles of TLR4 Gly299Gly (23.2% vs 8.0%; ; P ! .001 OR, 3.48) and TLR4 Ile399Ile (9.6% vs 3.7%;
; OR, P p .005 2.80) were significantly more common among patients with NCC than they were among control subjects. TLR4 variant allele frequency among control subjects was similar to that reported in an earlier study from our institution [27, 26] . Our results may suggest that these SNPs have a relevant role in determining NCC susceptibility.
Earlier reports suggested that chronic inflammation caused by up-regulation of proinflammatory cytokines might play a role in the development of symptomatic NCC [21, 28] . Studies using a murine model after T. crassiceps infection showed the involvement of neuropeptide (substance P) signaling in the production of proinflammatory cytokines, such as interleukin (IL)-1b, tumor necrosis factor a, and IL-6; blunted Th2 immune response was observed in the absence of neuropepetide (substance P) [19, 20] . Involvement of neuropeptide in human NCC remains unknown. There are only a few studies that have directly investigated the role of TLRs and their polymorphisms in immune response bias towards the anti-inflammatory phenotype [29] . Most of these polymorphism studies have been confined to the malarial parasite infection [30, 31] . Mockenhaupt et al [30] demonstrated that TLR4 Asp299Gly and Thr399Ile gene polymorphism conferred increased risks of severe malaria and were associated with disease manifestations. Any variation in the TLR4 gene results in altered or defective TLR4 signalling cascade, which modulates the immune response of the host.
There are limited studies, which demonstrate that helminthexpressed glycan activation of host immune cells accounts for much of the anti-inflammatory and Th2 biasing. Studies indicate that, in cases of NCC, there is a release of parasitic glycoproteins and glycolipids throughout the active infection period, and some of these molecules can act as specific PAMPs for particular TLRs [12] . Most of the targets for these glycans are members of the innate immune system. Thomas et al [15] showed that helminth glycans could act as PAMPs for inducing potent Th2 response via TLR4 dependent mechanism. Goodridge et al [32] even showed that secretory product (ES-62) from nematodes was involved in immune biasing via TLR4mediated mechanisms.
In the present study, we evaluated the possible association between genetic variations in the TLR4 gene and the clinical outcome of NCC. We hypothesized that genetic variations in the TLR4 gene may be associated with individual susceptibility to the development of symptomatic disease. The results indicate that the presence of TLR4 Asp299Gly and Thr399Ile genotypes increases the risk of developing NCC 4.57-fold and 3.39-fold, respectively, compared with wild-type (Table 3 ). In NCC, Th2 type immune response has been shown to be responsible for maintaining the asymptomatic condition, and alteration of the Th1/Th2 axis towards Th1 type has been shown to lead to the development of symptomatic NCC [21] .
We have found that degenerating cysts are significantly associated with symptomatic NCC, compared with asymptomatic NCC (20.73% vs 6.89%;
). However, the sample size P p .04 was quite low in our patient groups; therefore, we were not able to further analyze its association with TLR4 polymorphisms. There is limited data available, based on mouse models, regarding the expression of TLRs in NCC [12] . At present, there is no data available on TLR4 gene polymorphism in the context of NCC susceptibility. The data from the present study showed a significant association of TLR4 Asp299Gly and Thr399Ile gene polymorphism with symptomatic NCC, compared with control subjects (Asp/Gly, 59.8% vs 14.7%; P ! ; Thr/Ile, 26.8% vs 6.0%;
) (Table 4 ). On further .001 P ! .001 comparison of genotype frequency between symptomatic and asymptomatic NCC cases, we found TLR4 Asp/Gly and Thr/ Ile polymorphisms to be risk factors for the development of symptomatic NCC. However, we have not found any association of TLR4 Asp299Gly and Thr399Ile gene polymorphisms with asymptomatic cases. This raises a possibility that, in cases of symptomatic NCC, both of these polymorphisms play important roles in driving an immune response towards the Th1 phenotype. Our earlier study showed Th1 bias in symptomatic NCC [21] . Another study demonstrated that individuals who were heterozygous for Asp299Gly showed significantly up-regulated expression of proinflammatory cytokines but no difference in the production of anti-inflammatory cytokines [23] . TLR4 Asp299Gly and Thr399Ile gene polymorphisms result in strong variation in the region responsible for the recognition of PAMPs; thus, inducing altered signaling cascade on ligation with helminth glycan is responsible for modulating the immune response towards Th1 phenotype.
Furthermore, haplotype analysis showed that the frequency of heterozygous variant haplotype Gly/Thr (20.7% vs 4.3%;
; OR, 6.25) was significantly higher in case patients than P ! .001 in control subjects and conferred a 6.25-fold risk for susceptibility for NCC. Both TLR4 gene polymorphisms act in a dependent manner by affecting each other to impart susceptibility to NCC (Figure 1 ). It may be feasible that, in cases of NCC, both of these polymorphisms are involved in altering the immune function, which includes control of inflammatory cascades, elaboration of effector molecules, and interaction with adaptive immune responses. The Gly and Ile carriers are frequently found in NCC subjects (Table 3 ) and are also significantly associated with symptomatic NCC. Likewise, the Gly and Ile carriers were also observed to be risk factors for the development of symptomatic NCC, compared with asymptomatic NCC (Table 4 ).
In conclusion, the present study explored the contribution of TLR4 genetic polymorphism (Asp299Gly and Thr399Ile) in the development of symptomatic disease in individuals with NCC. The study identified TLR4 gene polymorphism as a risk factor for the development of symptomatic disease (active epilepsy) in patients with NCC. However, additional studies are needed to validate these findings in other ethnic groups from different geographic locales and to determine the molecular mechanism of these polymorphisms in the development of symptoms.
